Public drugmaker Pfenex Inc. is losing two of its top executives Chief Financial Officer Paul Wagner and Chief Manufacturing Officer Steve Sandoval.
Wagner, who’s been CFO of Pfenex since April 2014, is taking a new position within the industry. And Sandoval, who has served as CMO for a little over a year, is “pursuing other opportunities,” according to a company statement.
While Wagner is staying on until October 13, Sandoval’s departure is immediate. The company said it is searching for a replacement CFO, but did not address the vacant CMO position in its prepared statement.
Pfenex, a clinical-stage company, is developing biosimilar therapeutics, versions of branded therapeutic drugs that have or are about to reach patent expiry.